{"entity":{"type":"insider","cik":"0001591986","url":"/insider/0001591986","json_url":"/insider/0001591986.json","name":"Aquilo Capital Management, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":41,"n_filings":24,"first":"2020-07-22","last":"2022-09-26","span_basis":"filed_date"},"name_variants":[{"name":"Aquilo Capital Management, LLC","source":"filing","n_filings":24,"first_seen":"2020-07-22","last_seen":"2022-09-26"}],"transactions":[{"id":6869576,"accession":"0001591986-22-000018","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-22-000018","line_url":"/filing/0001591986-22-000018","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1901796.0,"shares_display":"1,901,796","price_per_share":2.2503,"price_display":"2.25","price_state":"stated","total_value":4279611.5388,"total_display":"4,279,611.54","total_whole":"4,279,612","shares_owned_after":3985719.0,"shares_owned_after_display":"3,985,719","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-22","filed_date":"2022-09-26","scope":"insider","n_lines":2},{"id":6906738,"accession":"0001591986-22-000015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-22-000015","line_url":"/filing/0001591986-22-000015#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":39727.0,"shares_display":"39,727","price_per_share":5.235,"price_display":"5.24","price_state":"stated","total_value":207970.845,"total_display":"207,970.84","total_whole":"207,971","shares_owned_after":5321231.0,"shares_owned_after_display":"5,321,231","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-04-26","filed_date":"2022-04-28","scope":"insider"},{"id":6609634,"accession":"0001591986-22-000014","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-22-000014","line_url":"/filing/0001591986-22-000014","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":8.7884,"price_display":"8.79","price_state":"stated","total_value":439420.0,"total_display":"439,420.00","total_whole":"439,420","shares_owned_after":5264619.0,"shares_owned_after_display":"5,264,619","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-30","filed_date":"2022-03-31","scope":"insider","n_lines":2},{"id":6906735,"accession":"0001591986-22-000013","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-22-000013","line_url":"/filing/0001591986-22-000013","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":23708.0,"shares_display":"23,708","price_per_share":7.626,"price_display":"7.63","price_state":"stated","total_value":180797.208,"total_display":"180,797.21","total_whole":"180,797","shares_owned_after":5223498.0,"shares_owned_after_display":"5,223,498","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-14","filed_date":"2022-03-16","scope":"insider","n_lines":2},{"id":6609625,"accession":"0001591986-22-000011","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-22-000011","line_url":"/filing/0001591986-22-000011","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":44833.0,"shares_display":"44,833","price_per_share":9.5293,"price_display":"9.53","price_state":"stated","total_value":427227.1069,"total_display":"427,227.11","total_whole":"427,227","shares_owned_after":5192692.0,"shares_owned_after_display":"5,192,692","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-28","filed_date":"2022-03-02","scope":"insider","n_lines":2},{"id":6401269,"accession":"0001591986-22-000010","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-22-000010","line_url":"/filing/0001591986-22-000010#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14828.0,"shares_display":"14,828","price_per_share":9.2419,"price_display":"9.24","price_state":"stated","total_value":137038.8932,"total_display":"137,038.89","total_whole":"137,039","shares_owned_after":5162963.0,"shares_owned_after_display":"5,162,963","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-18","filed_date":"2022-02-23","scope":"insider"},{"id":6791198,"accession":"0001591986-22-000004","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-22-000004","line_url":"/filing/0001591986-22-000004#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":125000.0,"shares_display":"125,000","price_per_share":11.5861,"price_display":"11.59","price_state":"stated","total_value":1448262.5,"total_display":"1,448,262.50","total_whole":"1,448,263","shares_owned_after":5148135.0,"shares_owned_after_display":"5,148,135","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-02-01","scope":"insider"},{"id":6102533,"accession":"0001591986-22-000003","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-22-000003","line_url":"/filing/0001591986-22-000003#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1599.0,"shares_display":"1,599","price_per_share":10.8931,"price_display":"10.89","price_state":"stated","total_value":17418.0669,"total_display":"17,418.07","total_whole":"17,418","shares_owned_after":5023135.0,"shares_owned_after_display":"5,023,135","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-24","filed_date":"2022-01-26","scope":"insider"},{"id":6609618,"accession":"0001591986-22-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-22-000002","line_url":"/filing/0001591986-22-000002#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":48488.0,"shares_display":"48,488","price_per_share":12.4147,"price_display":"12.41","price_state":"stated","total_value":601963.9736,"total_display":"601,963.97","total_whole":"601,964","shares_owned_after":5021536.0,"shares_owned_after_display":"5,021,536","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-18","filed_date":"2022-01-20","scope":"insider"},{"id":6939154,"accession":"0001591986-22-000001","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-22-000001","line_url":"/filing/0001591986-22-000001#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8867.0,"shares_display":"8,867","price_per_share":12.9253,"price_display":"12.93","price_state":"stated","total_value":114608.6351,"total_display":"114,608.64","total_whole":"114,609","shares_owned_after":4973048.0,"shares_owned_after_display":"4,973,048","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-10","filed_date":"2022-01-12","scope":"insider"},{"id":6707087,"accession":"0001691902-22-000001","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001691902-22-000001","line_url":"/filing/0001691902-22-000001#line-3","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":125000.0,"shares_display":"125,000","price_per_share":15.7522,"price_display":"15.75","price_state":"stated","total_value":1969025.0,"total_display":"1,969,025.00","total_whole":"1,969,025","shares_owned_after":4964181.0,"shares_owned_after_display":"4,964,181","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-31","filed_date":"2022-01-03","scope":"insider"},{"id":6707083,"accession":"0001691902-22-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001691902-22-000001","line_url":"/filing/0001691902-22-000001#line-2","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":15.7722,"price_display":"15.77","price_state":"stated","total_value":788610.0,"total_display":"788,610.00","total_whole":"788,610","shares_owned_after":4839181.0,"shares_owned_after_display":"4,839,181","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-30","filed_date":"2022-01-03","scope":"insider"},{"id":6707076,"accession":"0001691902-22-000001","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001691902-22-000001","line_url":"/filing/0001691902-22-000001#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":75493.0,"shares_display":"75,493","price_per_share":14.6406,"price_display":"14.64","price_state":"stated","total_value":1105262.8158,"total_display":"1,105,262.82","total_whole":"1,105,263","shares_owned_after":4789181.0,"shares_owned_after_display":"4,789,181","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-12-29","filed_date":"2022-01-03","scope":"insider"},{"id":4576470,"accession":"0001591986-21-000016","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000016","line_url":"/filing/0001591986-21-000016#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":17.5345,"price_display":"17.53","price_state":"stated","total_value":2630175.0,"total_display":"2,630,175.00","total_whole":"2,630,175","shares_owned_after":4713688.0,"shares_owned_after_display":"4,713,688","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-10-29","filed_date":"2021-11-02","scope":"insider"},{"id":4109372,"accession":"0001591986-21-000015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000015","line_url":"/filing/0001591986-21-000015#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":134543.0,"shares_display":"134,543","price_per_share":18.6496,"price_display":"18.65","price_state":"stated","total_value":2509173.1328,"total_display":"2,509,173.13","total_whole":"2,509,173","shares_owned_after":4563688.0,"shares_owned_after_display":"4,563,688","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-30","filed_date":"2021-10-04","scope":"insider"},{"id":4332709,"accession":"0001591986-21-000014","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-21-000014","line_url":"/filing/0001591986-21-000014#line-2","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2156.0,"shares_display":"2,156","price_per_share":18.4937,"price_display":"18.49","price_state":"stated","total_value":39872.4172,"total_display":"39,872.42","total_whole":"39,872","shares_owned_after":4429145.0,"shares_owned_after_display":"4,429,145","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-14","filed_date":"2021-09-15","scope":"insider"},{"id":4332705,"accession":"0001591986-21-000014","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000014","line_url":"/filing/0001591986-21-000014#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":44210.0,"shares_display":"44,210","price_per_share":18.5631,"price_display":"18.56","price_state":"stated","total_value":820674.651,"total_display":"820,674.65","total_whole":"820,675","shares_owned_after":4426989.0,"shares_owned_after_display":"4,426,989","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-13","filed_date":"2021-09-15","scope":"insider"},{"id":5077398,"accession":"0001591986-21-000013","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000013","line_url":"/filing/0001591986-21-000013#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24749.0,"shares_display":"24,749","price_per_share":18.4974,"price_display":"18.50","price_state":"stated","total_value":457792.1526,"total_display":"457,792.15","total_whole":"457,792","shares_owned_after":4382779.0,"shares_owned_after_display":"4,382,779","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-09","filed_date":"2021-09-10","scope":"insider"},{"id":4737844,"accession":"0001591986-21-000012","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-21-000012","line_url":"/filing/0001591986-21-000012#line-2","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":48645.0,"shares_display":"48,645","price_per_share":18.9261,"price_display":"18.93","price_state":"stated","total_value":920660.1345,"total_display":"920,660.13","total_whole":"920,660","shares_owned_after":4358030.0,"shares_owned_after_display":"4,358,030","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-31","filed_date":"2021-09-01","scope":"insider"},{"id":4737840,"accession":"0001591986-21-000012","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000012","line_url":"/filing/0001591986-21-000012#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":44042.0,"shares_display":"44,042","price_per_share":17.8661,"price_display":"17.87","price_state":"stated","total_value":786858.7762,"total_display":"786,858.78","total_whole":"786,859","shares_owned_after":4309385.0,"shares_owned_after_display":"4,309,385","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-30","filed_date":"2021-09-01","scope":"insider"},{"id":5442872,"accession":"0001591986-21-000011","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-21-000011","line_url":"/filing/0001591986-21-000011#line-2","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13957.0,"shares_display":"13,957","price_per_share":16.8755,"price_display":"16.88","price_state":"stated","total_value":235531.3535,"total_display":"235,531.35","total_whole":"235,531","shares_owned_after":4265343.0,"shares_owned_after_display":"4,265,343","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-27","filed_date":"2021-08-27","scope":"insider"},{"id":5442870,"accession":"0001591986-21-000011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000011","line_url":"/filing/0001591986-21-000011#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":22982.0,"shares_display":"22,982","price_per_share":16.5487,"price_display":"16.55","price_state":"stated","total_value":380322.2234,"total_display":"380,322.22","total_whole":"380,322","shares_owned_after":4251386.0,"shares_owned_after_display":"4,251,386","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-26","filed_date":"2021-08-27","scope":"insider"},{"id":4832420,"accession":"0001591986-21-000010","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001591986-21-000010","line_url":"/filing/0001591986-21-000010#line-3","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40170.0,"shares_display":"40,170","price_per_share":16.2757,"price_display":"16.28","price_state":"stated","total_value":653794.869,"total_display":"653,794.87","total_whole":"653,795","shares_owned_after":4228404.0,"shares_owned_after_display":"4,228,404","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-24","filed_date":"2021-08-24","scope":"insider"},{"id":4832413,"accession":"0001591986-21-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-21-000010","line_url":"/filing/0001591986-21-000010#line-2","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":137835.0,"shares_display":"137,835","price_per_share":16.3336,"price_display":"16.33","price_state":"stated","total_value":2251341.756,"total_display":"2,251,341.76","total_whole":"2,251,342","shares_owned_after":4188234.0,"shares_owned_after_display":"4,188,234","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-23","filed_date":"2021-08-24","scope":"insider"},{"id":4832406,"accession":"0001591986-21-000010","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000010","line_url":"/filing/0001591986-21-000010#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":221190.0,"shares_display":"221,190","price_per_share":14.8601,"price_display":"14.86","price_state":"stated","total_value":3286905.519,"total_display":"3,286,905.52","total_whole":"3,286,906","shares_owned_after":4050399.0,"shares_owned_after_display":"4,050,399","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-20","filed_date":"2021-08-24","scope":"insider"},{"id":4109368,"accession":"0001591986-21-000003","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000003","line_url":"/filing/0001591986-21-000003#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital Management, LLC; Aquilo Capital, L.P.","owner_display_name":"Aquilo Capital Management, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 Par Value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":21.7384,"price_display":"21.74","price_state":"stated","total_value":65215.2,"total_display":"65,215.20","total_whole":"65,215","shares_owned_after":3829209.0,"shares_owned_after_display":"3,829,209","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-10","scope":"insider"},{"id":5158329,"accession":"0001591986-21-000001","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001591986-21-000001","line_url":"/filing/0001591986-21-000001#line-4","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 Par Value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":34144.0,"shares_display":"34,144","price_per_share":18.9859,"price_display":"18.99","price_state":"stated","total_value":648254.5696,"total_display":"648,254.57","total_whole":"648,255","shares_owned_after":3832209.0,"shares_owned_after_display":"3,832,209","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-04","filed_date":"2021-02-04","scope":"insider"},{"id":5158322,"accession":"0001591986-21-000001","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001591986-21-000001","line_url":"/filing/0001591986-21-000001#line-3","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 Par Value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29354.0,"shares_display":"29,354","price_per_share":18.9787,"price_display":"18.98","price_state":"stated","total_value":557100.7598,"total_display":"557,100.76","total_whole":"557,101","shares_owned_after":3866353.0,"shares_owned_after_display":"3,866,353","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-03","filed_date":"2021-02-04","scope":"insider"},{"id":5158313,"accession":"0001591986-21-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-21-000001","line_url":"/filing/0001591986-21-000001#line-2","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 Par Value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22841.0,"shares_display":"22,841","price_per_share":18.9909,"price_display":"18.99","price_state":"stated","total_value":433771.1469,"total_display":"433,771.15","total_whole":"433,771","shares_owned_after":3895707.0,"shares_owned_after_display":"3,895,707","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-02","filed_date":"2021-02-04","scope":"insider"},{"id":5158304,"accession":"0001591986-21-000001","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-21-000001","line_url":"/filing/0001591986-21-000001#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 Par Value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13661.0,"shares_display":"13,661","price_per_share":19.2417,"price_display":"19.24","price_state":"stated","total_value":262860.8637,"total_display":"262,860.86","total_whole":"262,861","shares_owned_after":3918548.0,"shares_owned_after_display":"3,918,548","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-01","filed_date":"2021-02-04","scope":"insider"},{"id":2116603,"accession":"0001591986-20-000019","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-20-000019","line_url":"/filing/0001591986-20-000019#line-2","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250000.0,"shares_display":"250,000","price_per_share":18.8129,"price_display":"18.81","price_state":"stated","total_value":4703225.0,"total_display":"4,703,225.00","total_whole":"4,703,225","shares_owned_after":3932209.0,"shares_owned_after_display":"3,932,209","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-17","filed_date":"2020-12-18","scope":"insider"},{"id":2116600,"accession":"0001591986-20-000019","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-20-000019","line_url":"/filing/0001591986-20-000019#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14933.0,"shares_display":"14,933","price_per_share":18.6188,"price_display":"18.62","price_state":"stated","total_value":278034.5404,"total_display":"278,034.54","total_whole":"278,035","shares_owned_after":4182209.0,"shares_owned_after_display":"4,182,209","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-12-16","filed_date":"2020-12-18","scope":"insider"},{"id":2873413,"accession":"0001591986-20-000016","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-20-000016","line_url":"/filing/0001591986-20-000016#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125900.0,"shares_display":"125,900","price_per_share":13.7734,"price_display":"13.77","price_state":"stated","total_value":1734071.06,"total_display":"1,734,071.06","total_whole":"1,734,071","shares_owned_after":4197142.0,"shares_owned_after_display":"4,197,142","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-09","filed_date":"2020-11-10","scope":"insider"},{"id":2763901,"accession":"0001591986-20-000015","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001591986-20-000015","line_url":"/filing/0001591986-20-000015#line-3","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":13.7747,"price_display":"13.77","price_state":"stated","total_value":68873.5,"total_display":"68,873.50","total_whole":"68,874","shares_owned_after":4323042.0,"shares_owned_after_display":"4,323,042","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-06","filed_date":"2020-11-06","scope":"insider"},{"id":2763896,"accession":"0001591986-20-000015","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001591986-20-000015","line_url":"/filing/0001591986-20-000015#line-2","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":96600.0,"shares_display":"96,600","price_per_share":13.9786,"price_display":"13.98","price_state":"stated","total_value":1350332.76,"total_display":"1,350,332.76","total_whole":"1,350,333","shares_owned_after":4328042.0,"shares_owned_after_display":"4,328,042","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-05","filed_date":"2020-11-06","scope":"insider"},{"id":2763891,"accession":"0001591986-20-000015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-20-000015","line_url":"/filing/0001591986-20-000015#line-1","is_derivative":false,"issuer_cik":"0001491371","issuer_name":"Spero Therapeutics, Inc.","issuer_ticker":"SPRO","issuer_name_source":null,"issuer_url":"/issuer/0001491371","owner_cik":null,"owner_name":"Aquilo Capital, L.P.; Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":72500.0,"shares_display":"72,500","price_per_share":14.2585,"price_display":"14.26","price_state":"stated","total_value":1033741.25,"total_display":"1,033,741.25","total_whole":"1,033,741","shares_owned_after":4424642.0,"shares_owned_after_display":"4,424,642","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-04","filed_date":"2020-11-06","scope":"insider"},{"id":2930984,"accession":"0001591986-20-000011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001591986-20-000011","line_url":"/filing/0001591986-20-000011#line-1","is_derivative":false,"issuer_cik":"0001583648","issuer_name":"PIERIS PHARMACEUTICALS, INC.","issuer_ticker":"PIRS","issuer_name_source":null,"issuer_url":"/issuer/0001583648","owner_cik":"0001591986","owner_name":"Aquilo Capital Management, LLC","owner_display_name":"Aquilo Capital Management, LLC","owner_url":"/insider/0001591986","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1900000.0,"shares_display":"1,900,000","price_per_share":2.95,"price_display":"2.95","price_state":"stated","total_value":5605000.0,"total_display":"5,605,000.00","total_whole":"5,605,000","shares_owned_after":3675530.0,"shares_owned_after_display":"3,675,530","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-21","filed_date":"2020-07-22","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":1,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":1,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":1},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001701108","name":"Spero Therapeutics, Inc.","url":"/issuer/0001701108","role":"Ten percent owner","n_filings":23,"first_seen":"2020-11-06","last_seen":"2022-09-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001583648","name":"PIERIS PHARMACEUTICALS, INC.","url":"/issuer/0001583648","role":"Ten percent owner","n_filings":1,"first_seen":"2020-07-22","last_seen":"2020-07-22"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001591986","retrieved_at":"2026-08-23T08:53:11+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}